New injection could help obese patients breathe easier at night
NCT ID NCT07501832
First seen Apr 07, 2026 · Last updated May 13, 2026 · Updated 2 times
Summary
This study tests an investigational drug called GZR18 in 140 obese adults with moderate-to-severe obstructive sleep apnea who already use a breathing machine (PAP). The goal is to see if the drug can reduce breathing pauses during sleep and help with weight loss. Participants will receive either GZR18 or a placebo injection for 52 weeks, and researchers will measure changes in sleep apnea severity and quality of life.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OBSTRUCTIVE SLEEP APNEA (OSA) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Gan & Lee Pharmaceuticals
Beijing, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.